Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LNG015
MIFTS: 46

Lingual-Facial-Buccal Dyskinesia

Categories: Neuronal diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Lingual-Facial-Buccal Dyskinesia

About this section

MalaCards integrated aliases for Lingual-Facial-Buccal Dyskinesia:

Name: Lingual-Facial-Buccal Dyskinesia 12 15 74
Orofacial Dyskinesia 30 6
Oro-Facial Dyskinesia 12
Dyskinesias 45

Classifications:

MalaCards categories:
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:9854
ICD9CM 36 333.82
MeSH 45 D020820
SNOMED-CT 69 49386006
ICD10 34 G24.4
UMLS 74 C0152115
Sources

Summaries for Lingual-Facial-Buccal Dyskinesia

About this section
MalaCards based summary : Lingual-Facial-Buccal Dyskinesia, also known as orofacial dyskinesia, is related to tardive dyskinesia and movement disease, and has symptoms including spasmodic torticollis An important gene associated with Lingual-Facial-Buccal Dyskinesia is CSTB (Cystatin B), and among its related pathways/superpathways are Peptide ligand-binding receptors and Circadian entrainment. The drugs Methylcobalamin and Hydroxocobalamin have been mentioned in the context of this disorder. Affiliated tissues include heart, brain and globus pallidus, and related phenotypes are behavior/neurological and nervous system

Sources

Related Diseases for Lingual-Facial-Buccal Dyskinesia

About this section

Diseases related to Lingual-Facial-Buccal Dyskinesia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 401)
# Related Disease Score Top Affiliating Genes
1 tardive dyskinesia 32.7 DRD2 DRD3
2 movement disease 30.4 DRD2 DRD3
3 choreoacanthocytosis 30.1 VPS13A XK
4 mood disorder 30.0 DRD2 DRD3 DRD4
5 parkinson disease, late-onset 29.9 DRD1 DRD2 DRD3
6 schizoaffective disorder 29.8 DRD2 DRD3
7 disease of mental health 29.8 DRD2 DRD3 DRD4
8 restless legs syndrome 29.8 DRD2 DRD3
9 early-onset schizophrenia 29.8 DRD1 DRD2
10 major depressive disorder 29.7 DRD2 DRD3 DRD4
11 gilles de la tourette syndrome 29.7 DRD2 DRD4 DRD5
12 dystonia 29.6 CSTB DRD2 DRD5
13 impulse control disorder 29.5 DRD2 DRD3 DRD4
14 bruxism 29.2 DRD2 DRD3 DRD5
15 alcohol dependence 29.0 DRD1 DRD2 DRD3 DRD4
16 substance abuse 28.8 DRD2 DRD3 DRD4 DRD5
17 schizophrenia 28.4 DRD1 DRD2 DRD3 DRD4 DRD5
18 attention deficit-hyperactivity disorder 28.4 DRD1 DRD2 DRD3 DRD4 DRD5
19 primary ciliary dyskinesia 12.6
20 episodic kinesigenic dyskinesia 1 12.5
21 ciliary dyskinesia, primary, 3 12.5
22 ciliary dyskinesia, primary, 9 12.5
23 ciliary dyskinesia, primary, 1 12.5
24 ciliary dyskinesia, primary, 7 12.5
25 ciliary dyskinesia, primary, 5 12.5
26 ciliary dyskinesia, primary, 19 12.5
27 ciliary dyskinesia, primary, 20 12.5
28 ciliary dyskinesia, primary, 15 12.5
29 ciliary dyskinesia, primary, 16 12.5
30 ciliary dyskinesia, primary, 17 12.5
31 ciliary dyskinesia, primary, 35 12.5
32 paroxysmal nonkinesigenic dyskinesia, 3, with or without generalized epilepsy 12.5
33 ciliary dyskinesia, primary, 27 12.5
34 ciliary dyskinesia, primary, 21 12.5
35 ciliary dyskinesia, primary, 26 12.5
36 ciliary dyskinesia, primary, 28 12.5
37 ciliary dyskinesia, primary, 11 12.5
38 ciliary dyskinesia, primary, 2 12.5
39 ciliary dyskinesia, primary, 12 12.5
40 ciliary dyskinesia, primary, 13 12.5
41 ciliary dyskinesia, primary, 18 12.5
42 ciliary dyskinesia, primary, 23 12.5
43 ciliary dyskinesia, primary, 22 12.4
44 ciliary dyskinesia, primary, 30 12.4
45 ciliary dyskinesia, primary, 29 12.4
46 adcy5-related dyskinesia 12.4
47 ciliary dyskinesia, primary, 33 12.4
48 biliary dyskinesia 12.4
49 ciliary dyskinesia, primary, 32 12.4
50 drug induced dyskinesia 12.4

Graphical network of the top 20 diseases related to Lingual-Facial-Buccal Dyskinesia:



Diseases related to Lingual-Facial-Buccal Dyskinesia
Sources

Symptoms & Phenotypes for Lingual-Facial-Buccal Dyskinesia

About this section

UMLS symptoms related to Lingual-Facial-Buccal Dyskinesia:


spasmodic torticollis

MGI Mouse Phenotypes related to Lingual-Facial-Buccal Dyskinesia:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.5 CSTB DRD1 DRD2 DRD3 DRD4 DRD5
2 nervous system MP:0003631 9.23 CSTB DRD1 DRD2 DRD3 DRD4 DRD5
Sources

Drugs & Therapeutics for Lingual-Facial-Buccal Dyskinesia

About this section

Drugs for Lingual-Facial-Buccal Dyskinesia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 22)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylcobalamin Approved, Experimental, Investigational Phase 2, Phase 3 13422-55-4
2
Hydroxocobalamin Approved Phase 2, Phase 3 13422-51-0 15589840 11953898
3
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
4
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 2, Phase 3,Phase 3 65-23-6 1054
5
Cyanocobalamin Approved, Nutraceutical Phase 2, Phase 3 68-19-9 44176380
6
Cobalamin Experimental Phase 2, Phase 3 13408-78-1 6857388
7 Vitamin B 6 Phase 2, Phase 3
8 Vitamins Phase 2, Phase 3
9 Central Nervous System Depressants Phase 2, Phase 3
10 Vitamin B Complex Phase 2, Phase 3
11 Trace Elements Phase 2, Phase 3
12 Tranquilizing Agents Phase 2, Phase 3
13 Hematinics Phase 2, Phase 3
14 Vitamin B9 Phase 2, Phase 3
15 Psychotropic Drugs Phase 2, Phase 3
16 Folate Phase 2, Phase 3
17 Vitamin B12 Phase 2, Phase 3
18 Micronutrients Phase 2, Phase 3
19 Nutrients Phase 2, Phase 3
20 Vitamin B 12 Phase 2, Phase 3
21 Antipsychotic Agents Phase 2, Phase 3
22
Pyridoxal Experimental, Nutraceutical Phase 2, Phase 3 66-72-8 1050

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics Not yet recruiting NCT03790345 Phase 2, Phase 3 Pyridoxine;Cobalamin;Placebo Oral Tablet
2 ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders Recruiting NCT02252380 Not Applicable
3 Effect of tDCS on Cognition, Symptoms in Chronic Schizophrenia Patients With Tardive Dyskinesia Recruiting NCT03497013 Not Applicable

Search NIH Clinical Center for Lingual-Facial-Buccal Dyskinesia

Cochrane evidence based reviews: dyskinesias

Sources

Genetic Tests for Lingual-Facial-Buccal Dyskinesia

About this section

Genetic tests related to Lingual-Facial-Buccal Dyskinesia:

# Genetic test Affiliating Genes
1 Orofacial Dyskinesia 30
Sources

Anatomical Context for Lingual-Facial-Buccal Dyskinesia

About this section

MalaCards organs/tissues related to Lingual-Facial-Buccal Dyskinesia:

42
Heart, Brain, Globus Pallidus, Caudate Nucleus, Lung, Eye, Breast
Sources

Publications for Lingual-Facial-Buccal Dyskinesia

About this section

Articles related to Lingual-Facial-Buccal Dyskinesia:

(show top 50) (show all 99)
# Title Authors Year
1
Possible nitric oxide mechanism involved in the protective effect of L-theanine on haloperidol-induced orofacial dyskinesia. ( 30942195 )
2019
2
Dexmethylphenidate Extended Release-Associated Orofacial Dyskinesia in an Adolescent with Autism Spectrum Disorder After Prolonged Use. ( 29781724 )
2018
3
Management of Refractory Orofacial Dyskinesia Caused by Anti-N-methyl-d-aspartate Receptor Encephalitis Using Botulinum Toxin. ( 29520252 )
2018
4
Protective effect of hesperetin against haloperidol-induced orofacial dyskinesia and catalepsy in rats. ( 28641484 )
2018
5
L-Theanine Decreases Orofacial Dyskinesia Induced by Reserpine in Rats. ( 29629512 )
2018
6
Acute-onset Orofacial Dyskinesia with a Single Low Dose of Oral Flupentixol: A Case Report. ( 29962578 )
2018
7
Clozapine-Induced Microseizures, Orofacial Dyskinesia, and Speech Dysfluency in an Adolescent with Treatment Resistant Early Onset Schizophrenia on Concurrent Lithium Therapy. ( 28835863 )
2017
8
Beneficial effects of lycopene against haloperidol induced orofacial dyskinesia in rats: Possible neurotransmitters and neuroinflammation modulation. ( 26712377 )
2016
9
Plasmodium falciparum and Mycoplasma pneumoniae co-infection presenting with cerebral malaria manifesting orofacial dyskinesia and haemophagocytic lymphohistiocytosis. ( 27609213 )
2016
10
Ginkgo biloba leaf extract and alpha-tocopherol attenuate haloperidol-induced orofacial dyskinesia in rats: Possible implication of antiapoptotic mechanisms by preventing Bcl-2 decrease and Bax elevation. ( 27823630 )
2016
11
Crocin prevents haloperidol-induced orofacial dyskinesia: possible an antioxidant mechanism. ( 27872703 )
2016
12
(-) Epigallocatechin-3-gallate attenuates reserpine-induced orofacial dyskinesia and oxidative stress in rat striatum. ( 25668129 )
2015
13
Effect of ethanolic extract of Coriandrum sativum L. on tacrine induced orofacial dyskinesia. ( 26040026 )
2015
14
Management of Edentulous Orofacial Dyskinesia. ( 26329418 )
2015
15
Orofacial Dyskinesia in Elderly. ( 30838247 )
2015
16
Teaching video neuroimages: orofacial dyskinesia and oral ulceration due to involuntary biting in neuroacanthocytosis. ( 24566231 )
2014
17
Orofacial dyskinesia associated with the use of levofloxacin. ( 24259611 )
2014
18
Prolonged consumption of trans fat favors the development of orofacial dyskinesia and anxiety-like symptoms in older rats. ( 24625052 )
2014
19
Neurosyphilis orofacial dyskinesia: the candy sign. ( 23166011 )
2013
20
Phenytoin-induced acute orofacial dyskinesia. ( 22595500 )
2013
21
Orofacial dyskinesia induced by nasal Ritalin(R) (methylphenidate) sniffing: a rare case report from Switzerland. ( 23174746 )
2013
22
Protective effect of Rubia cordifolia on reserpine-induced orofacial dyskinesia. ( 22092272 )
2012
23
Reversal of haloperidol-induced orofacial dyskinesia by Murraya koenigii leaves in experimental animals. ( 22136413 )
2012
24
Nicotine reduces antipsychotic-induced orofacial dyskinesia in rats. ( 22144565 )
2012
25
Ethanolic extract of Rubia peregrina L. (Rubiaceae) inhibits haloperidol-induced catalepsy and reserpine-induced orofacial dyskinesia. ( 22316173 )
2012
26
Reversal of reserpine-induced orofacial dyskinesia and catalepsy by Nardostachys jatamansi. ( 22701243 )
2012
27
Orofacial dyskinesia after moxifloxacin treatment--a case with normal hepatorenal function and review of literature. ( 23151468 )
2012
28
Protective Effect of Leaves of Murraya koenigii on Reserpine-Induced Orofacial Dyskinesia. ( 24250488 )
2012
29
Korean ginseng extract attenuates reserpine-induced orofacial dyskinesia and improves cognitive dysfunction in rats. ( 20628966 )
2011
30
Mucuna pruriens attenuates haloperidol-induced orofacial dyskinesia in rats. ( 20635303 )
2011
31
B vitamins attenuate haloperidol-induced orofacial dyskinesia in rats: possible involvement of antioxidant mechanisms. ( 21918383 )
2011
32
Protective effect of Morus alba leaves on haloperidol-induced orofacial dyskinesia and oxidative stress. ( 20645751 )
2010
33
Protective effects of aqueous fruit extract from Sea Buckthorn (Hippophae rhamnoides L. Spp. Turkestanica) on haloperidol-induced orofacial dyskinesia and neuronal alterations in the striatum. ( 20671610 )
2010
34
Modafinil-induced orofacial dyskinesia in an elderly patient with refractory bipolar depression. ( 21037146 )
2010
35
Co-administration of nitric oxide (NO) donors prevents haloperidol-induced orofacial dyskinesia, oxidative damage and change in striatal dopamine levels. ( 18789960 )
2009
36
Phenotype of spontaneous orofacial dyskinesia in neuregulin-1 'knockout' mice. ( 19150478 )
2009
37
Progesterone attenuates neuroleptic-induced orofacial dyskinesia via the activity of its metabolite, allopregnanolone, a positive GABA(A) modulating neurosteroid. ( 17988775 )
2008
38
Protective effect of Curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain. ( 18022680 )
2008
39
Protective effect of L-type calcium channel blockers against haloperidol-induced orofacial dyskinesia: a behavioural, biochemical and neurochemical study. ( 18363098 )
2008
40
Differential striatal levels of TNF-alpha, NFkappaB p65 subunit and dopamine with chronic typical and atypical neuroleptic treatment: role in orofacial dyskinesia. ( 18554768 )
2008
41
Activation of striatal inflammatory mediators and caspase-3 is central to haloperidol-induced orofacial dyskinesia. ( 18590723 )
2008
42
Protective effect of adenosine reuptake inhibitors in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes. ( 17377417 )
2007
43
Possible anti-oxidant and neuroprotective mechanisms of zolpidem in attenuating typical anti-psychotic-induced orofacial dyskinesia: a biochemical and neurochemical study. ( 17513028 )
2007
44
Valeriana officinalis does not alter the orofacial dyskinesia induced by haloperidol in rats: role of dopamine transporter. ( 17669571 )
2007
45
Orofacial dyskinesia, frontal lobe dysfunction, and coping in older people with psychosis. ( 17804832 )
2007
46
Protective effect of rutin, a polyphenolic flavonoid against haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes. ( 17868205 )
2007
47
Ilex paraguariensis has antioxidant potential and attenuates haloperidol-induced orofacial dyskinesia and memory dysfunction in rats. ( 17967741 )
2007
48
Orofacial dyskinesia associated with tiemonium. ( 18034667 )
2007
49
U-74500A (lazaroid), a 21-aminosteroid attenuates neuroleptic-induced orofacial dyskinesia. ( 18193111 )
2007
50
Effect of Withania somnifera root extract on reserpine-induced orofacial dyskinesia and cognitive dysfunction. ( 16444668 )
2006
Sources

Variations for Lingual-Facial-Buccal Dyskinesia

About this section

ClinVar genetic disease variations for Lingual-Facial-Buccal Dyskinesia:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 CSTB NM_000100.3(CSTB): c.202C> T (p.Arg68Ter) single nucleotide variant Pathogenic rs74315442 GRCh37 Chromosome 21, 45194178: 45194178
2 CSTB NM_000100.3(CSTB): c.202C> T (p.Arg68Ter) single nucleotide variant Pathogenic rs74315442 GRCh38 Chromosome 21, 43774297: 43774297
3 46;XX;t(2;14)(q21;q24.3)dn Translocation Uncertain significance
4 HERC2 NM_004667.5(HERC2): c.5045A> G (p.Asn1682Ser) single nucleotide variant Uncertain significance GRCh37 Chromosome 15, 28474681: 28474681
5 HERC2 NM_004667.5(HERC2): c.5045A> G (p.Asn1682Ser) single nucleotide variant Uncertain significance GRCh38 Chromosome 15, 28229535: 28229535
6 RYR1 NM_000540.2(RYR1): c.1312G> C (p.Glu438Gln) single nucleotide variant Uncertain significance GRCh37 Chromosome 19, 38943526: 38943526
7 RYR1 NM_000540.2(RYR1): c.1312G> C (p.Glu438Gln) single nucleotide variant Uncertain significance GRCh38 Chromosome 19, 38452886: 38452886
Sources

Expression for Lingual-Facial-Buccal Dyskinesia

About this section
Search GEO for disease gene expression data for Lingual-Facial-Buccal Dyskinesia.
Sources

Pathways for Lingual-Facial-Buccal Dyskinesia

About this section

Pathways related to Lingual-Facial-Buccal Dyskinesia according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Peptide ligand-binding receptors 67
Show member pathways
 13.19 DRD1 DRD2 DRD3 DRD4 DRD5 XK
2
Circadian entrainment 38
Show member pathways
 12.67 DRD1 DRD2 DRD3 DRD4 DRD5
3
Beta-Adrenergic Signaling 65
Show member pathways
 12.42 DRD1 DRD2 DRD3 DRD4 DRD5
5
cAMP signaling pathway 38
11.98 DRD1 DRD2 DRD5
6
Dopamine-DARPP32 Feedback onto cAMP Pathway 65
11.91 DRD1 DRD2 DRD3 DRD4 DRD5
7
Long-term potentiation 38
Show member pathways
 11.78 DRD1 DRD2 DRD4 DRD5
8
Nicotine Pathway (Dopaminergic Neuron), Pharmacodynamics 62
Show member pathways
 11.64 DRD2 DRD3 DRD4
9
Monoamine GPCRs 1
Show member pathways
 11.4 DRD1 DRD2 DRD3 DRD4 DRD5
10
Microglia Activation During Neuroinflammation: Steady-State Microglia 66
11.15 DRD1 DRD2
11
DARPP-32 Phosphorylation 66
10.27 DRD1 DRD2 DRD3 DRD5
Sources

GO Terms for Lingual-Facial-Buccal Dyskinesia

About this section

Cellular components related to Lingual-Facial-Buccal Dyskinesia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.77 DRD1 DRD2 DRD3 DRD4 DRD5
2 glutamatergic synapse GO:0098978 9.56 DRD1 DRD2 DRD3 DRD4
3 integral component of presynaptic membrane GO:0099056 9.46 DRD1 DRD2
4 endocytic vesicle GO:0030139 9.43 DRD2 DRD3
5 integral component of postsynaptic membrane GO:0099055 9.4 DRD1 DRD2
6 GABA-ergic synapse GO:0098982 9.33 DRD1 DRD2 DRD3
7 dopaminergic synapse GO:0098691 9.32 DRD2 DRD3
8 ciliary membrane GO:0060170 9.13 DRD1 DRD2 DRD5
9 non-motile cilium GO:0097730 8.8 DRD1 DRD2 DRD5

Biological processes related to Lingual-Facial-Buccal Dyskinesia according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.89 DRD1 DRD2 DRD3
2 autophagy GO:0006914 9.86 DRD2 DRD3 VPS13A
3 cellular calcium ion homeostasis GO:0006874 9.84 DRD3 DRD4 DRD5 XK
4 locomotory behavior GO:0007626 9.83 DRD1 DRD2 DRD3 VPS13A
5 social behavior GO:0035176 9.79 DRD3 DRD4 VPS13A
6 visual learning GO:0008542 9.77 DRD1 DRD2 DRD3
7 associative learning GO:0008306 9.75 DRD1 DRD2 DRD5
8 negative regulation of blood pressure GO:0045776 9.74 DRD2 DRD3 DRD5
9 protein localization GO:0008104 9.73 DRD2 VPS13A
10 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.73 DRD1 DRD4
11 arachidonic acid secretion GO:0050482 9.73 DRD2 DRD3 DRD4
12 response to cocaine GO:0042220 9.73 DRD1 DRD2 DRD3 DRD5
13 learning GO:0007612 9.72 DRD1 DRD3
14 synapse assembly GO:0007416 9.72 DRD1 DRD2
15 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.72 DRD2 DRD3
16 adult locomotory behavior GO:0008344 9.72 CSTB DRD4
17 circadian regulation of gene expression GO:0032922 9.72 DRD2 DRD3
18 negative regulation of protein secretion GO:0050709 9.72 DRD2 DRD3 DRD4
19 negative regulation of protein kinase B signaling GO:0051898 9.71 DRD2 DRD3
20 regulation of synaptic vesicle exocytosis GO:2000300 9.71 DRD1 DRD2
21 positive regulation of cytokinesis GO:0032467 9.71 DRD2 DRD3
22 activation of adenylate cyclase activity GO:0007190 9.7 DRD1 DRD5
23 feeding behavior GO:0007631 9.7 DRD1 DRD2
24 adult walking behavior GO:0007628 9.7 DRD1 DRD2
25 behavioral fear response GO:0001662 9.7 DRD1 DRD4
26 response to morphine GO:0043278 9.69 DRD2 DRD3
27 temperature homeostasis GO:0001659 9.69 DRD1 DRD2
28 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.69 DRD2 DRD3
29 prepulse inhibition GO:0060134 9.69 DRD1 DRD2 DRD3
30 transmission of nerve impulse GO:0019226 9.68 DRD1 DRD5
31 long-term synaptic depression GO:0060292 9.68 DRD1 DRD5
32 striatum development GO:0021756 9.68 DRD1 DRD2
33 grooming behavior GO:0007625 9.67 DRD1 DRD2
34 positive regulation of renal sodium excretion GO:0035815 9.67 DRD2 DRD3
35 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.67 DRD1 DRD3 DRD5
36 G protein-coupled receptor internalization GO:0002031 9.66 DRD2 DRD3
37 regulation of postsynaptic neurotransmitter receptor internalization GO:0099149 9.66 DRD3 DRD4
38 peristalsis GO:0030432 9.65 DRD1 DRD2
39 regulation of dopamine metabolic process GO:0042053 9.65 DRD1 DRD4
40 behavioral response to ethanol GO:0048149 9.65 DRD2 DRD4
41 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.65 DRD2 DRD3 DRD4
42 negative regulation of voltage-gated calcium channel activity GO:1901386 9.64 DRD2 DRD4
43 mating behavior GO:0007617 9.64 DRD1 DRD5
44 cellular response to catecholamine stimulus GO:0071870 9.63 DRD1 DRD5
45 cerebral cortex GABAergic interneuron migration GO:0021853 9.63 DRD1 DRD2
46 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.63 DRD1 DRD2 DRD5
47 negative regulation of dopamine receptor signaling pathway GO:0060160 9.62 DRD2 DRD3
48 behavioral response to cocaine GO:0048148 9.62 DRD1 DRD2 DRD3 DRD4
49 acid secretion GO:0046717 9.61 DRD2 DRD3
50 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.61 DRD2 DRD4

Molecular functions related to Lingual-Facial-Buccal Dyskinesia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.77 DRD1 DRD2 DRD3 DRD4 DRD5
2 drug binding GO:0008144 9.5 DRD2 DRD3 DRD4
3 G-protein alpha-subunit binding GO:0001965 9.43 DRD1 DRD5
4 adrenergic receptor activity GO:0004935 9.4 DRD2 DRD3
5 dopamine binding GO:0035240 9.35 DRD1 DRD2 DRD3 DRD4 DRD5
6 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.33 DRD2 DRD3 DRD4
7 dopamine neurotransmitter receptor activity, coupled via Gs GO:0001588 9.26 DRD1 DRD5
8 dopamine neurotransmitter receptor activity GO:0004952 9.02 DRD1 DRD2 DRD3 DRD4 DRD5
Sources

Sources for Lingual-Facial-Buccal Dyskinesia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....